Schedule 13D ownership disclosure
CAMP4 Therapeutics Corp.
Common Stock, $0.0001 par value per share · CUSIP: 13463J101
Event date: 2026-03-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Enavate Sciences GP, LLCReported CIK 0001953107
Shares: 2,495,562.00 · Class: 4.8%
- Everest Aggregator, LPReported CIK 0002040426
Shares: 2,495,562.00 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001953107-26-000005
- Form type
- SCHEDULE 13D/A
- Filer
- Camp4 Therapeutics Corp
- CIK
- CIK 1736730
- Filed
- Mar 11, 2026
- Reporting period
- Mar 09, 2026
- Description
- Schedule 13D beneficial ownership